Biogen and Sage Therapeutics have entered a global collaboration and licence agreement to jointly develop and commercialise depression and tremor therapies, zuranolone (SAGE-217) and SAGE-324, respectively.

Under the deal, Sage will get $1.525bn in cash which includes an upfront payment of $875m and $650m as an equity investment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

On achieving certain development and commercial milestones in zuranolone and SAGE-324 programmes, Sage is eligible to get up to $1.6bn as potential milestone payments.

Zuranolone is a potential two-week, once-daily oral therapy being developed for treating major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric disorders.

The treatment is currently in Phase III development as part of the LANDSCAPE and NEST clinical programmes.

A positive allosteric modulator of GABA receptors, SAGE-324 is under evaluation for essential tremor and other neurological conditions like epilepsy and PD as part of Phase II development.

Biogen CEO Michel Vounatsos said: “We are excited about the potential to bring together Biogen’s leading capabilities in neuroscience with Sage’s deep expertise in psychiatry.”

The companies will share responsibility and costs for development and profits and losses for commercialisation in the US.

According to the deal, Biogen will have exclusive licence to develop and commercialise zuranolone and SAGE-324 outside of the US, excluding rights to zuranolone in Japan, Taiwan and South Korea.

Furthermore, Sage will receive tiered royalties from Biogen.

Sage Therapeutics chief operating officer Mike Cloonan said: “With the recent and pending data outputs for zuranolone and SAGE-324, the timing is right for a collaboration between two like-minded companies committed to patients and driven by a passion for neuroscience and brain health.”

The closing of the deal should take place by the end of January.

In August, Biogen signed a binding agreement with Denali Therapeutics to develop and commercialise therapeutics for Parkinson’s disease.